Literature DB >> 14530869

P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells.

Anna Bielak-Mijewska1, Katarzyna Piwocka, Adriana Magalska, Ewa Sikora.   

Abstract

PURPOSE: One of the mechanisms responsible for the multidrug resistance (MDR) phenotype of cancer cells is overexpression of so-called ATP-dependent drug efflux proteins: the 170-kDa P-glycoprotein (P-gp) encoded by the MDR1 gene and the 190-kDa multidrug resistance-associated protein 1 encoded by the MRP1 gene. The purpose of the present study was to verify the hypothesis postulating that P-gp expression, apart from enabling drug efflux, confers on the cells resistance to apoptosis by inhibiting caspase-8 and caspase-3.
MATERIALS AND METHODS: Human HL-60 cells, either drug-sensitive or with the MDR phenotype caused by overexpression of P-gp (HL-60/Vinc) or MRP1 (HL-60/Adr), were treated with the natural dye curcumin at 50 micro M or with UVC to induce apoptosis. Symptoms of cell death were assessed by morphological observation after Hoechst staining, DNA fragmentation was measured by flow cytometry and the TUNEL method, and caspase-8 and caspase-3 activation and cytochrome c release from mitochondria were measured by Western blotting.
RESULTS: Curcumin induced cell death in HL-60 cells, both sensitive and with the MDR phenotype, which could be classified as caspase-3-dependent apoptosis, together with cytochrome c release, activation of caspase-3 and oligonucleosomal DNA fragmentation. No active caspase-8 was detected. Also UVC caused caspase-3 activation in both the sensitive and the MDR HL-60 cells.
CONCLUSIONS: Our findings show that there was no correlation between P-gp expression and resistance to caspase-3-dependent apoptosis induced by curcumin and UVC, at least in HL-60 cells. However, we cannot exclude the possibility of parallel P-gp expression and caspase-3 inhibition in some other cell lines, as cancer cells can acquire many different apoptosis-resistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530869     DOI: 10.1007/s00280-003-0705-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Curcumin disrupts meiotic and mitotic divisions via spindle impairment and inhibition of CDK1 activity.

Authors:  A Bielak-Zmijewska; M Sikora-Polaczek; K Nieznanski; G Mosieniak; A Kolano; M Maleszewski; J Styrna; E Sikora
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

Review 2.  Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing.

Authors:  Muobarak Jaber Tuorkey
Journal:  Interv Med Appl Sci       Date:  2014-12-22

Review 3.  Curcumin and Gastric Cancer: a Review on Mechanisms of Action.

Authors:  Tohid Hassanalilou; Saeid Ghavamzadeh; Leila Khalili
Journal:  J Gastrointest Cancer       Date:  2019-06

Review 4.  Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Authors:  Natale D'Alessandro; Paola Poma; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

5.  bis-Dehydroxy-Curcumin triggers mitochondrial-associated cell death in human colon cancer cells through ER-stress induced autophagy.

Authors:  Valentina Basile; Silvia Belluti; Erika Ferrari; Chiara Gozzoli; Sonia Ganassi; Daniela Quaglino; Monica Saladini; Carol Imbriano
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

6.  Curcumin in cell death processes: a challenge for CAM of age-related pathologies.

Authors:  S Salvioli; E Sikora; E L Cooper; C Franceschi
Journal:  Evid Based Complement Alternat Med       Date:  2007-04-23       Impact factor: 2.629

Review 7.  New insights into therapeutic activity and anticancer properties of curcumin.

Authors:  Abir Kumar Panda; Dwaipayan Chakraborty; Irene Sarkar; Tila Khan; Gaurisankar Sa
Journal:  J Exp Pharmacol       Date:  2017-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.